Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 262.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.46M |
| Shares Out | 84.70M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,264 |
| Open | 3.100 |
| Previous Close | 3.120 |
| Day's Range | 3.050 - 3.150 |
| 52-Week Range | 1.930 - 4.387 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+158.48%) |
| Earnings Date | Aug 13, 2025 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 158.48% from the latest price.
News
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressi...
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, to...
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials a...
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has...
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive sa...
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT ® -
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, a...
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones The overview presentation will review some of the Company's recent a...
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference
JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, an...
Alpha Tau Treats First Patient with Recurrent Lung Cancer
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, a...
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - -Trial to focus on particularly vulnerable subs...
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cance...
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow -
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...